Cerebrospinal fluid tau, phospho‐tau181 and β‐amyloid1−42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The aim of the present study was the quantitation of total tau protein (τT), tau phosphorylated at threonine 181 (τP‐181) and β‐amyloid 1−42 (A β 42) in the cerebrospinal fluid (CSF) of patients with idiopathic normal pressure hydrocephalus (iNPH), Alzheimer's disease (AD) and controls. Double sandwich ELISAs (Innogenetics) were used for the measurements. Total tau was significantly increased in iNPH and highly increased in AD as compared with the control group, whilst A β 42 was decreased in both diseases. CSF τP−181 levels were significantly increased only in AD, but not in iNPH as compared with the controls. A cut‐off level for τT at 300 pg/ml, successfully discriminated AD from normal aging with a 95.8% specificity and 91% sensitivity; whilst the τP‐181/τT ratio (cut‐off value 0.169) was more specific (100%) but less sensitive (92.5%). For the discrimination of iNPH from AD τT achieved low specificity (77.8%) but high sensitivity (92.5%), whilst τP‐181 (cut‐off value 47.4) was both sensitive and specific (88.7% and 86.7% respectively) for the discrimination of these disorders. The present study, despite being clinical, supports the notion that CSF τP‐181 alone or in combination with τT may be a useful marker in the discrimination of iNPH from AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 1×
“Total tau (sT) is clearly increased in the CSF of AD patients, even at the early stages [3].”
BackgroundBlennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724
Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response
Golomb, J. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.6.778 · Cited by 279 · cited 2×
“However, there are data suggesting that even in iNPH cases with AD comorbidity, shunting may have some benefit on motor but not in mental function [24].”
BackgroundJohnson, G. V. W., Seubert, P., Cox, T. M., Motter, R., Brown, J. P., & Galasko, D. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68010430.x · Cited by 162
Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
Arai, H., Morikawa, Y.-I., Higuchi, M., Matsui, T., Clark, C. M., Miura, M., Machida, N., Lee, V. M.-Y., Trojanowski, J. Q., & Sasaki, H. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6908 · Cited by 159 · cited 1×
“levels have been reported to correlate with the number of neurofibrillary tangles in AD leading to the speculation that CSF sT elevation is a marker of tauopathic abnormalities [4,5].”
Background
Cited by
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus: Second Edition
MORI, E., ISHIKAWA, M., KATO, T., KAZUI, H., MIYAKE, H., MIYAJIMA, M., NAKAJIMA, M., HASHIMOTO, M., KURIYAMA, N., TOKUDA, T., et al. (2012) · Neurologia medico-chirurgica · doi:10.2176/nmc.52.775 · Cited by 666
NAKAJIMA, M., YAMADA, S., MIYAJIMA, M., ISHII, K., KURIYAMA, N., KAZUI, H., KANEMOTO, H., SUEHIRO, T., YOSHIYAMA, K., KAMEDA, M., et al. (2021) · Neurologia medico-chirurgica · doi:10.2176/nmc.st.2020-0292 · Cited by 594
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease
Hampel, H., Bürger, K., Teipel, S. J., Bokde, A. L. W., Zetterberg, H., & Blennow, K. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.08.006 · Cited by 532
Total and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389
Metadata
- Authors
- Kapaki, E. N., Paraskevas, G. P., Tzerakis, N. G., Sfagos, C., Seretis, A., Kararizou, E., & Vassilopoulos, D.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2007-01-23
- Volume
- 14
- Issue
- 2
- Pages
- 168-173
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2083984894
- Cited by
- 140
- References
- 6
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cerebrospinal fluid tau, phospho‐tau181 and β‐amyloid1−42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. https://app.cochat.ai/papers/10.1111/j.1468-1331.2006.01593.x
- The paper
- Kapaki, E. N., Paraskevas, G. P., Tzerakis, N. G., Sfagos, C., Seretis, A., Kararizou, E., & Vassilopoulos, D. (2007). Cerebrospinal fluid tau, phospho‐tau181 and β‐amyloid1−42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2006.01593.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.